Journal Mobile Options
Table of Contents
Vol. 35, No. 4, 2003
Issue release date: July–August 2003
Ophthalmic Res 2003;35:199–207

Expression of Tissue Inhibitor of Metalloproteinase-4 in Normal Human Corneal Cells and Experimental Corneal Neovascularization

Ma D.H.-K. · Zhang F. · Shi W. · Yao J.-Y. · Hsiao C.-H. · Wu H.C. · Kim W.-S. · Hao Y.-X. · Hwang D.G. · Chen J.-K. · Tsai R.J.-F.
aDepartment of Ophthalmology, Chang-Gung Memorial Hospital, Taoyuan, Taiwan; bOcular Cell and Gene Therapy Laboratory, Department of Ophthalmology, University of California, San Francisco, Calif., USA; cExelixis, South San Francisco, Calif., USA; dMaryknoll Hospital, and ePusan National University, Pusan, Korea; fDepartment of Physiology, Chang-Gung University, Taoyuan, Taiwan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Purpose: To study the expression of TIMP-4 in cultured corneal cells and in corneal neovascularization. Methods: Human limbo-corneal epithelial cells, fibroblasts, and endothelial cells were cultured in serum-free, PMA- or basic fibroblast growth factor (bFGF)-treated condition. Neovascularization in rat cornea was induced by suturing. The expression of TIMP-4 was examined by immunohistochemistry, Western blot and RT-PCR. Results: TIMP-4 was constitutively expressed in cultured human corneal cells. The expression was only mildly enhanced after mitogen treatment. TIMP-4 immunoreactivity was predominantly expressed in normal rat corneal epithelium, and also in ingrowing blood vessels following suturing, which persisted up to day 28. Increased staining in corneal epithelium and blood vessels were also noted in vascularized human corneas. Conclusions: TIMP-4 is expressed in the cornea, which may play a role in modulating extracellular matrix remodeling associated with corneal wound healing and angiogenesis.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Casey R, Li WW: Factors controlling ocular angiogenesis. Am J Ophthalmol 1997;124:521–529.
  2. Cao Y: Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357–369.
  3. Senger DR: Molecular framework for angiogenesis: A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines [comment]. Am J Pathol 1996;149:1–7.
  4. Hernandez-Quintela E, Azar DT, O’Reilly MS: The role of angiostatin in the cornea after wounding. Invest Ophthalmol Vis Sci 1999;40:S97.
  5. Lin HC, Chang JH, Jain S, Gabison EE, Kure T, Kato T, Fukai N, Azar DT: Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kD fragment. Invest Ophthalmol Vis Sci 2001;42:2517–2524.
  6. Hiscott P, Seitz B, Schlotzer-Schrehardt U, Naumann GO: Immunolocalization of thrombospondin 1 in human, bovine, and rabbit cornea. Cell Tissue Res 1997;289:307–310.
  7. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999;285:245–248.
  8. Peek R, van Gelderen BE, Bruinenberg M, Kijlstra A: Molecular cloning of a new angiopoietin-like factor from the human cornea. Invest Ophthalmol Vis Sci 1998;39:1782–1788.
  9. Tervo T, Tervo K, van Setten GB, Virtanen I, Tarkksnen A: Plasminogen activator and its inhibitor in the experimental corneal wound. Exp Eye Res 1989;48:445–449.
  10. Mirshahi M, Mirshahi S, Soria C, Soria J, Thornaidis A, Pouliguen Y, Faure JP: Production of proteases type plasminogen activators and their inhibitor in cornea. Biochem Biophy Res Commun 1989;160:1021–1025.
  11. Williams DL, Risse B, Kim S, Saunders D, Orlin S, Baker MS, Jensen PJ, Lavker RM: Plasminogen activator inhibitor type 2 in human corneal epithelium. Invest Ophthalmol Vis Sci 1999;40:1669–1675.
  12. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111–122.
  13. Johnson MD, Kim HR, Chesler L, Tsa-Wu G, Bouck N, Polverini PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194–202.
  14. Murphy AN, Unsworth EJ, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351–358.
  15. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D’Orazi G, Murphy AN, Bird RE, Hoythya M, Fuerst TR, French DL, et al: Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235–246.
  16. Anand-Apte B, Pepper MS, Voest E, Montesano R, Olsen B, Murphy G, Apte SS, Zetters BR: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997;38:817–823.
  17. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767–2774.

    External Resources

  18. Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG: MMP-2: Expression, activation and inhibition. Enzyme Protein 1996;49:7–19.
  19. Yu AE, Murphy AN, Stetler-Stevenson WG: 72-kD gelatinase (gelatinase A): Structure, activation, regulation, and substrate specificity; in Parks WC, Mecham RP (eds): Matrix Metalloproteinases. San Diego, Academic Press, 1998, pp 85–113.
  20. Liu YE, Wang M, Greene J, Su J, Ullrich S, Li H, Sheng S, Alexander P, Sang QA, Shi YE: Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4). J Biol Chem 1997;272:20479–20483.
  21. Kenney MC, Chwa M, Alba A, Saghizadeh M, Huang ZS, Brown DT: Localization of TIMP-1, TIMP-2, TIMP-3, gelatinase A and gelatinase B in pathological human corneas. Curr Eye Res 1998;17:238–246.
  22. Alexander JP, Samples JR, Van Buskirk EM, Acott TS: Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 1991;32:172–180.
  23. Alexander JP, Samples JR, Acott TS: Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res 1998;17:276–285.
  24. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A: Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998;39:2194–2200.
  25. Della NG, Campochiaro PA, Zack DJ: Localization of TIMP-3 mRNA expression to the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1996;37:1921–1924.
  26. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996;271:30375–30380.
  27. Li YY, Feldman A, Sun Y, McTiernan CF: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728–1734.
  28. Wu I, Moses MA: Molecular cloning and expression analysis of the cDNA encoding rat tissue inhibitor of metalloproteinase-4. Matrix Biol 1998;16:339–342.
  29. Ma DH, Chen JK, Kim WS, Hao YX, Wu HC, Tsai RJ, Hwang DG, Zhang F: Expression of matrix metalloproteinase-2, -9 and tissue inhibitor of metalloproteinase-1, -2 in inflammation-induced corneal neovascularization. Ophthalmic Res 2001;33:353–362.
  30. Kvanta A, Sarman S, Fagerholm P, Sergard S, Steen B: Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000;70:419–428.
  31. Zhang H, Li C, Baciu PC: Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2002;43:955–962.
  32. Tsai RJ, Ho YS, Chen JK: The effects of fibroblasts on the growth and differentiation of human bulbar conjunctival epithelial cells in an in vitro conjunctival equivalent. Invest Ophthalmol Vis Sci 1994;35:2865–2875.
  33. Vranka JA, Johnson E, Zhu X, Shepardson A, Alexander JP, Brandley JM, Wirtz MK, Weleber RG, Klein ML, Acott TS: Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid. Curr Eye Res 1997;16:102–110.
  34. Dana MR, Streilein JW: Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996;39:2245–2251.
  35. Dana MR, Zhu SN, Yamada J: Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea 1998;17:403–409.
  36. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269:9352–9360.
  37. Ries C, Petrides PE: Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler 1995;376:345–355.
  38. Moses MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997;15:180–189.
  39. Mignatti P, Rifkin DB: Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49:117–137.
  40. Pintucci G, Bikfalvi A, Klein S, Rifkin DB: Angiogenesis and the fibrinolytic system. Semin Thromb Hemost 1996;22:517–524.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50